DOJ

Subscribe to DOJ via RSS

Amid the chaos of the past few weeks—sweeping executive orders, relentless cost-cutting, and an air of uncertainty that lingers like smoke after a fire—federal contractors have been left reeling, straining to hear what comes next through the deafening noise. In this storm, predicting the future is as futile as fortune-telling. And yet beneath the shouts of change and upheaval, one truth remains, a whisper through the screams—some things, especially those that serve the government’s interests, are not going anywhere.Continue Reading Whisper Through the Screams: DOJ Commits to False Claims Act Enforcement in 2025

Johnny, rosin up your bow and play your fiddle hard
’Cause Hell’s broke loose in Georgia and the Devil deals the cards
And if you win, you get this shiny fiddle made of gold
But if you lose the Devil gets your soul
~ The Charlie Daniels Band

Some might say there’s little difference between dealing with the devil and being a federal contractor. And for the unwary or unprepared, that may not be far off. Federal contracting comes with a litany of “fine print” that would make “Old Scratch” proud. However, as most savvy contractors recognize, it’s all hiding in plain sight, with the devil in the details. Take, for example, the cybersecurity requirements found in the Federal Acquisition Regulations (FAR) at 52.204-21 and the Department of Defense (DoD) FAR Supplement (DFARS) at 252.204-7012, -7019, and -7020. These requirements have been the topic of countless articles, trainings, webinars, whole conferences, etc., so it is surprising while simultaneously not surprising that they form the basis of a federal False Claims Act (FCA) claim the Department of Justice (DOJ) recently filed in its complaint in intervention.Continue Reading DOJ Went Down to Georgia: Lessons Learned from Recent Cybersecurity Enforcement Actions

In United States ex rel. Silver v. Omnicare, Inc., et al. (D.N.J. No. 11-cv-01326), a whistleblower relator consistently alleged that certain pharmaceutical service providers have engaged in an illegal kickback arrangement and defrauded the government by offering unreasonably low prices to nursing homes for Medicare Part A patients’ prescription drugs in exchange for the opportunity to provide the same drugs at much higher costs to the nursing homes’ Medicaid and Medicare Part D patients for reimbursement. In a recent Order, the federal district court in New Jersey revived previously dismissed claims and permitted the relator to file a new, and fourth, amended complaint that asserts a new theory of liability to buttress the core kickback scheme allegations. The new complaint asserts that prescription drug event (PDE) data and enrollee encounter data are “claims for payment” under the False Claims Act (FCA)—and that even accurate PDE data can be a “false claim” under the FCA in cases where a pharmacy is alleged to pay kickbacks to its customers.
Continue Reading How the Truth Is False: Accurate Prescription Drug Event Data Can Trigger False Claims Act Liability

For several years, we have witnessed the emergence of a statutory and regulatory framework to tighten controls on the export of emerging and critical technology, as well as the review of inward foreign investment into said technology. As was evident in the listing of Huawei and other Chinese technology giants, the United States has demonstrated a willingness to use alternative punitive measures against China. Whether the desired impact of this approach has been achieved is difficult to determine. We have, nevertheless, no reason to believe that the tide will ebb in 2020.
Continue Reading Export Controls and Global Trade: A Forecast and the Year in Review